Chronic, long term asthma results in a change in patients’ lungs leading to wheezing, frequent infections, and low quality of life. The current treatments are aimed at managing the condition and its symptoms. There are not treatments for asthmatics with severe, steroid resistant asthma. We have found that reducing a key asthma lung marker results in reversal of the asthma phenotype with the lung cells now resembling non-asthmatic healthy cells. Our proposed oral therapeutic based on this marker will allow asthma sufferers to live relatively free from this often-debilitating chronic respiratory disorder.
|Effective start/end date||20/09/21 → 31/12/21|
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.